Daratumumab and hyaluronidase-fihj received FDA approval for high-risk smoldering multiple myeloma, showing significant PFS ...
The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback